Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy

A Double-blind Placebo-controlled Randomized Clinical Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00911365

Enrollment

Registered

2009-06-01

Start date

2008-05-31

Completion date

2011-06-30

Last updated

2011-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple System Atrophy

Keywords

voluntary participants, 75 years old or less

Brief summary

This study is based on positive results in open label trial of mesenchymal stem cells therapy in patients with Multiple System Atrophy (MSA).

Interventions

BIOLOGICALautologous mesenchymal stem cells

4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly -\> Total four times

BIOLOGICALnormal saline

saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

No minimum to 75 Years

Healthy volunteers

Inclusion criteria

* 75 Years Old or Less * Multiple System Atrophy * Voluntary Participants

Exclusion criteria

* Doubted dementia (MMSE \< 24) * Severe febrile condition * Serum SGOT/SGPT three times above * Malignant mass

Design outcomes

Primary

Measure	Time frame	Description
Scores on unified MSA rating scale	one month	The statistical difference between scores before and after autologous mesenchymal stem cells treatment of unified MSA rating scale will be measured every month and every year using paired t-test.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026